Primmune Therapeutics

📍 San Diego, United States🗓 Founded 2017👥 10 employees💰 Last funded Jan 2026
Biotechnology Research🌐 primmunerx.com
Website LinkedIn
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

1 investor
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Primmune Therapeutics?
Primmune Therapeutics has 1 investor on record on gritt.io and 1 late-stage investors.
When did Primmune Therapeutics last raise funding?
The most recent investment in Primmune Therapeutics recorded on gritt.io was in January 2026.
When was Primmune Therapeutics founded?
Primmune Therapeutics was founded in 2017.
What industry is Primmune Therapeutics in?
Primmune Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Primmune Therapeutics based?
Primmune Therapeutics is headquartered in San Diego, United States.